[Federal Register Volume 65, Number 133 (Tuesday, July 11, 2000)]
[Notices]
[Pages 42699-42704]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-17445]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 00143]


Intervention Epidemiologic Research Studies of HIV/AIDS; Notice 
of Availability of Funds

A. Purpose

    The Centers for Disease Control and Prevention (CDC) announces the 
availability of fiscal year (FY) 2000 funds for a cooperative agreement 
program to (1) continue the longitudinal epidemiologic study of 
perinatal HIV transmission and pediatric disease progression during an 
era of highly active antiretroviral (ARV) therapy and (2) develop and 
implement innovative interventions to assist HIV infected children and 
adolescents (both perinatally and non-perinatally infected) in 
accessing and maintaining comprehensive HIV related care. The 
interventions will be directed at sustaining HIV specialist care, 
improving adherence to complex medical regimens, promoting overall and 
reproductive health, and decreasing the risk of secondary transmission 
of HIV infection. This program addresses the ``Healthy People 2010'' 
priority area of HIV Infection and Maternal and Infant Health. For a 
conference copy of ``Healthy People 2010'' visit the internet site: 
http://www.health.gov/healthy people>.
    The purpose of the program is to support three research studies of 
programmatic interest to the health care community that fosters 
prevention of HIV-related disease in infants, children, and 
adolescents. These studies include: (1) Ongoing longitudinal record 
review of Pediatric HIV disease, (2) development and evaluation of 
innovative intervention(s) to enhance sustained HIV specialist care and 
improved adherence to antiretroviral (ARV) medication drug regimens in 
children, from 5-12 years of age, and (3) development and evaluation of 
innovative interventions to provide linkages to and help sustain 
continuity of HIV specialist care, to foster adherence to HIV therapy, 
improve overall and reproductive health, and reduce transmission from 
HIV-infected adolescents ages 13-21 years, to others.
    The following three Research Studies will be supported:

I. Ongoing Longitudinal Record Review Study of Pediatric HIV Disease

    Competing continuation applications are invited for the continued 
prospective follow-up of HIV-infected children enrolled in the 
Pediatric Spectrum of Disease (PSD) Study between 1988 and 2000. 
Continued research areas of interest include:
    A. Perinatal HIV Prevention
    1. Characterization of perinatally infected infants with respect to 
their risk factors for HIV infection and clinical and laboratory 
outcomes.
    2. Investigation of potential severe adverse events related to 
exposure to antiretrovirals and/or other HIV-related therapies.

[[Page 42700]]

    3. Description of circumstances of delivery and associated infant 
and maternal morbidities.
    4. Frequency and description of birth outcomes to perinatally-
infected adolescents.
    B. Pediatric and Adolescent Management:
    1. Factors associated with health and disease progression:
    a. Viral load and ARV resistance
    b. Immune function and reconstitution
    c. Growth and development, including puberty
    d. Timing, type, and duration of therapy
    e. Factors affecting adherence (including HIV infection status 
disclosure)
    f. Potential side effects of ARV therapy
    2. Identification of barriers to:
    a. Timely receipt of care
    b. Durability of relationship with providers
    3. Description of family structure and social risk factors
    4. Characterization of developmental needs and linkage to special 
services for HIV-infected adolescents (e.g. health, family planning, 
STD clinic services, case management around HIV disease, etc.)

II. Innovative Intervention(s) To Enhance Sustained HIV Specialist Care 
and Improved Adherence to Antiretroviral Medication Drug Regimens in 
Children, From 5-12 Years of Age

    The complex nature of combination antiretroviral regimens 
emphasizes the need to develop innovative interventions to help 
children adhere to prescribed drug therapy. Age-appropriate 
interventions need to be designed and evaluated for both perinatally 
and non-perinatally infected children. Applications are invited to 
propose and develop intervention trials for children with evidence of 
current disease progression or treatment failure. The intent is to 
examine the impact of intervention strategies which address the 
following issues:
    A. Fostering sustained comprehensive HIV specialist care:
    1. Assessing barriers to sustaining continuity of specialist HIV 
care.
    2. Developing and implementing strategies (e.g. reminders, support 
groups, etc.) to overcome individual and family barriers including HIV 
disclosure issues.
    3. Linking to services which enable continuity of specialist HIV 
care. (e.g. transportation, day care, family-based care, education, 
etc.)
    4. Developing and implementing methods for locating and re-engaging 
children lost to follow-up.
    B. Promoting adherence to medications:
    1. Assessing individual and family barriers to adherence to 
medication.
    2. Linking to services which facilitate adherence (medication 
education, case management, social, pharmacist, etc.)
    3. Developing and implementing strategies (e.g. dosing and 
medication schedules, child's preferences, in-home assistance, out-of-
home adherence, reminders, use of MEMSCaps, support groups, 
etc.) to overcome individual and family barriers including HIV 
disclosure issues.

III. Innovative Interventions to Provide Linkages to and Help Sustain 
Continuity of HIV Specialist Care, To Foster Adherence to HIV Therapy, 
To Improve Overall and Reproductive Health, and To Reduce Secondary 
Transmission Among Perinatally or Non-Perinatally HIV-Infected 
Adolescents, From 13-21 Years of Age

    Applications are invited that propose interventions that are 
developmentally focused, targeting issues of importance to adolescents 
and young adults, and address two or more of the following issues:
    A. Linking to HIV specialist care:
    1. Identifying HIV counseling and testing sites where HIV-infected 
adolescents are diagnosed.
    2. Developing and documenting the procedures for referring 
identified HIV infected adolescents from counseling/testing sites to 
HIV specialist care providers appropriate for adolescents.
    3. Facilitating the follow through of referrals made to HIV 
specialist care providers.
    B. Maintaining continuity of HIV specialist care.
    1. Assessing barriers to sustaining continuity of specialist HIV 
care.
    2. Linking to services which enable continuity of specialist HIV 
care. (e.g. education, social, etc.)
    3. Developing and implementing strategies to overcome individual, 
family or social barriers including HIV disclosure issues (reminders, 
support groups, etc.)
    4. Developing and implementing age appropriate and culturally 
relevant strategies for locating and re-engaging adolescents lost to 
follow-up.
    C. Promoting adherence to medication regimens:
    1. Assessing individual, family and social barriers to adherence to 
medication.
    2. Linking to services which facilitate adherence (medication 
education, case management, social, pharmacist, etc.)
    3. Developing and implementing strategies to overcome individual, 
family and social barriers, including addressing HIV disclosure issues 
(dosing and medication schedules, adolescent's preferences, in-home 
assistance, reminders, etc.).
    D. Develop interventions to support overall and reproductive health 
of adolescents and that decrease secondary HIV transmission.
    1. Developing and implementing counseling strategies for HIV 
infected adolescents designed to improve their overall and reproductive 
health and decrease risk of secondary transmission of HIV (e.g. by 
prevention of sexually transmitted diseases, decreasing risky sexual 
behaviors, avoidance of illicit drug use, etc.)
    2. Evaluating the effectiveness of the counseling intervention.

B. Eligible Applicants

    Applications may be submitted by public and private nonprofit 
organizations and by governments and their agencies; that is, 
universities, colleges, research institutions, hospitals, other public 
and private nonprofit organizations, State and local governments or 
their bona fide agents, and federally recognized Indian tribal 
governments, Indian tribes, or Indian tribal organizations.
    For research study area I, (longitudinal medical record review), 
eligible applicants include only those grantees currently funded for 
the Pediatric Spectrum of HIV Disease (PSD) Project under CDC Program 
Announcement 735. These sites include Children's National Medical 
Center, (Washington, DC), the Puerto Rico Department of Health, the 
University of Massachusetts Medical Center, the Texas Department of 
Health, the Public Health Foundation Enterprises, Inc. (Los Angeles), 
and the New York City Department of Health.

    Note: Public Law 104-65 states that an organization described in 
section 501(c)(4) of the Internal Revenue Code of 1986 that engages 
in lobbying activities is not eligible to receive Federal funds 
constituting an award, grant, cooperative agreement, contract, loan, 
or any other form.

C. Availability of Funds

    I. Research area I: Approximately $1.6 million is available in FY 
2000 to fund approximately 6 competitive continuation projects. It is 
expected that the average award will be $260,000, ranging from $180,000 
to $500,000.
    II. Research area II: Approximately $200,000 is available in FY 
2000 to fund approximately 2 awards for innovative intervention(s) for 
children 5-12 years

[[Page 42701]]

of age. It is expected that the average award will be $100,000.
    III. Research area III: Approximately $200,000 is available in FY 
2000 to fund approximately 2 awards for innovative interventions for 
adolescents 13-21 years of age. It is expected that the average award 
will be $100,000.
    It is expected that all awards will begin on or about September 30, 
2000, and will be made for a 12-month budget period, within a project 
period of up to 4 years. Funding estimates may change.
    Continuation awards within an approved project period will be made 
on the basis of satisfactory progress as evidenced by required reports 
and the availability of funds.

D. Program Requirements

    In conducting activities to achieve the purpose of this program, 
the recipient will be responsible for the activities listed under
    1. (Recipient Activities), and CDC will be responsible for 
conducting activities listed under 2. (CDC Activities).

1. Recipient Activities

    Applicants addressing the same research issue should be willing to 
participate in collaborative studies with other CDC-sponsored 
researchers, including developing and using common data collection 
instruments, specimen collection protocols, and data management 
procedures, as determined in post-award grantee planning conferences. 
Recipients will be required to pool data for analysis and publication. 
Recipients are also required to work collaboratively as a study group 
to:
    a. Develop the research study protocols and standardized data 
collection forms across sites.
    b. Identify, recruit, obtain informed consent from, and enroll an 
adequate number of study participants as determined by the study 
protocols and the program requirements.
    c. Follow study participants as determined by the study protocols.
    d. Establish procedures to maintain the rights and confidentiality 
of all study participants.
    e. Perform laboratory tests (when appropriate) and data analysis as 
determined in the study protocols.
    f. Collaborate and share data and specimens (when appropriate) with 
other collaborators to answer specific research questions.
    g. Contribute blood specimens for drug resistance and therapeutic 
drug level studies for the intervention studies depending on the 
protocol requirements, for shipment and storage at a centralized 
repository system at CDC.
    h. Conduct data analysis with all collaborators as well as present 
and publish research findings.
    i. Attend biannual meetings with other funded grantees.

2. CDC Activities

    a. Provide technical assistance as needed in the design and conduct 
of the research.
    b. Facilitate and assist in the development of a research protocol 
for Institutional Review Board (IRB) review by all cooperating 
institutions participating in the research project. The CDC IRB will 
review and approve the protocol initially and on at least an annual 
basis until the research project is completed.
    c. Assist as needed in designing a data management system.
    d. Assist as needed in performance of selected laboratory tests.
    e. Work collaboratively with investigators to help facilitate 
research activities across sites involved in the same research project.
    f. Assist in the analysis of research information and the 
presentation and publication of research findings.

E. Application Content

    Use the information in the Program Requirements, Other 
Requirements, and Evaluation Criteria sections to develop your 
application. Your application will be evaluated on the criteria listed, 
so it is important to follow them in laying out your program plan. 
Follow the directions for completing the application that are found in 
the Public Health Service (PHS) 398 kit. If you are applying for more 
than one activity, you must submit a separate application for each 
research area.

F. Submission and Deadline

    Submit the original and five copies of PHS-398 (OMB Number 0925-
0001) (adhere to the instructions on the Errata Instruction Sheet for 
PHS 398). Forms are available at the following Internet address: 
www.cdc.gov/...Forms, or in the application kit. On or before August 
21, 2000, submit the application to the Grants Management Specialist 
identified in the ``Where to Obtain Additional Information'' section of 
this announcement.
    Deadline: Applications shall be considered as meeting the deadline 
if they are either:
    (a) Received on or before the deadline date; or
    (b) Sent on or before the deadline date and received in time for 
submission to the independent review group. Applicants must request a 
legibly dated U.S. Postal Service postmark or obtain a legibly dated 
receipt from a commercial carrier or U.S. Postal Service. Private 
metered postmarks shall not be acceptable as proof of timely mailing.
    Late Applications: Applications that do not meet these criteria are 
considered late applications, will not be considered, and will be 
returned to the applicant.

G. Evaluation Criteria

    Each application will be evaluated individually against the 
following criteria by an independent review group appointed by CDC. 
Applicants will be ranked on a scale of 100 maximum points according to 
the research area identified. All applicants must state which research 
category they are addressing. Applications must demonstrate the 
applicant's ability to address the research in a collaborative manner 
with other recipients. Applications will be reviewed and evaluated 
based on the information submitted, as they specifically describe the 
applicant's abilities to meet the following criteria:

1. Familiarity With and Access To Study Population (25 Points)

    a. Description of population to be studied, including number, age 
distribution, and other relevant demographic characteristics is 
described. The number of HIV-exposed (for Part I) and HIV-infected 
enrollees (for Parts I-III) to be prospectively monitored, and expected 
attrition from deaths and losses to follow-up over the study period 
based on prior experience is specified.
    b. Description of the most important trends in disease progression, 
HIV and other health care needs, including gaps in services, of the 
population to be studied (e.g. HIV-exposed children, HIV-infected 
children, HIV-infected adolescents, HIV-infected mothers).
    c. Ability to access and review neonatal, pediatric, adolescent and 
maternal prenatal and labor and delivery records. (Part I)
    d. Ability to recruit at least 100 children for the pediatric 
intervention (Part II) or 50 adolescents for the adolescent 
intervention. (Part III)
    e. Ability to identify and follow HIV-exposed but HIV-uninfected 
children and HIV-infected children for Part I, HIV-infected children 
between 5-12 years of age for Part II, and HIV-infected adolescents 
between 13-21 years of age for Part III. In addition:
    (1) For part I, describes the plan to match HIV-exposed children 
over time (as long as they are followed in the study and after they are 
lost to follow-

[[Page 42702]]

up) with death, congenital birth defect, cancer and other registries to 
investigate potential severe side effects of antiretroviral exposure.
    (2) For Part III, describes the sites where the majority of HIV-
infected adolescents are being diagnosed (if ``linkages to care'' is 
included as a research area).
    f. Prior research with or service provision to the study population 
and linkages and collaboration with other organizations providing 
medical and psychosocial services to the study population. As 
appropriate, include memoranda of agreement to document collaboration 
with organizations providing services to the study population.
    g. Feasibility of plans for involving the service providers in the 
design and implementation of research activities.
    h. Extent to which intervention plans take developmental stages 
into account and are appropriate for the population described. (Parts 
II and III)
    i. Existence of linkages to facilitate monitoring the study 
population (all parts) including memoranda of agreement from the 
clinical facilities to permit record review. (Part I)
    j. Demonstrated collaboration with local health departments and 
pediatric HIV/AIDS surveillance staff. (Part I)

2. Description and Justification of Research Plans (25 Points)

    a. Quality of the review of the scientific literature pertinent to 
the proposed activities, including justification for and relevance of 
research questions and the proposed intervention. The research issues 
and a description of which ones must be addressed are described under 
the Purpose/Areas of Research section.
    b. The applicant's understanding of the research objectives as 
evidenced by high quality of the proposed research plan.
    c. The scientific soundness of the methods described by the 
applicant to:
    (1) Abstract data and assure adequate follow-up of the pediatric, 
adolescent and maternal populations and timely completion of data forms 
and transfer of data to CDC (Part I)
    (2) Develop and evaluate interventions in children 5-12 years of 
age (Part II), including:
    (i) Review laboratory and disease indicators of (highly 
antiretroviral therapy) HAART failure in children 5-12 years of age 
(e.g. CD4 counts, HIV viral loads, history of AIDS defining 
conditions);
    (ii) Interview children and their parents about factors potentially 
relevant to the children's treatment failure or success;
    (iii) Design and operationalize standard and enhanced innovative 
interventions;
    (iv) Randomize participants to one of the interventions and deliver 
the interventions;
    (v) Monitor participants through the end of the study (e.g. monitor 
adherence to medications, measure drug levels, review laboratory and 
disease indicators of HAART failure, collect blood spots to measure ARV 
drug resistance); and
    (vi) Evaluate the effectiveness of the interventions, including its 
cost-effectiveness.
    (vii) Develop and deliver an intervention to HIV-infected 
adolescents from 13-21 years of age, monitor participants through the 
end of the study and evaluate the effectiveness of the intervention 
(Part III).
    d. Ability and feasibility of collecting additional information 
from the medical records around the following areas (for Part I):
    (1) Issues specific to adolescents;
    (2) Issues specific to adherence to medical regimens; and
    (3) Laboratory results related to ARV drug resistance.
    e. Adequacy of methods for quality assurance including: Supervision 
of data abstraction, entry and cleaning, validation of accuracy and 
completeness of data abstraction and data entry, maintenance of 
consistency in methodology used by abstractors and data entry clerks in 
their procedures, and monitoring of study progress (Part I).
    (1) Training and supervision of staff conducting interventions to 
ensure consistency in the methodology used for the intervention across 
all participants. (Parts II and III)
    (2) Tracking follow-up of HIV-exposed children (Part I), HIV-
infected children (Parts I and II), HIV-infected adolescents (Parts I 
and III) and HIV-infected mothers (Part I). This should include a 
description of the experience of the investigator in enrolling and 
monitoring the population to be studied (all parts) and the procedures 
used to ensure that participants will complete the interventions. 
(Parts II and III)
    f. Scientific soundness, creativity and thoroughness of plans to 
analyze local data using quantitative methods and statistical 
techniques. (Parts I, II, and III).
    g. Extent to which the intervention (Parts II and III):
    (1) Represents an innovative approach.
    (2) Meets unmet needs.
    (3) Complements existing interventions.
    (4) Avoids duplication of efforts.
    (5) Incorporates cutting edge technology (e.g., MEMSCaps, 
computer based interviews).
    h. Adequacy of plans to disseminate research findings locally 
(including local collaborating service providers and participants of 
the study).
    i. Extent to which study proposal demonstrates assurance of 
compliance with multisite research requirements (e.g., common protocol, 
data collection, and computer and data management systems).
    j. The degree to which the applicant has met the CDC Policy 
requirements regarding the inclusion of ethnic and racial groups in the 
proposed research. This includes: (1) The proposed plan for the 
inclusion of racial and ethnic minority populations for appropriate 
representation; (2) The proposed justification when representation is 
limited or absent; (3) A statement as to whether the design of the 
study is adequate to measure differences when warranted; (4) A 
statement as to whether the plans for recruitment and outreach for 
study participants include the process of establishing partnerships 
with communities and recognition of mutual benefits.
    k. Extent to which application identifies and discusses any 
potential ethical issues associated with the proposed research and 
describes how these issues will be resolved.
    (1) Describes procedures for obtaining IRB approval and maintaining 
participant confidentiality.
    (2) Describes whether there are any additional IRB issues involved 
in: Reviewing mothers' medical records (Part I.) and matching ARV-
exposed children to other registries after they are lost to follow-up 
to identify potential long term severe side effects which might be 
associated with ARV prophylaxis (e.g., how long can names be maintained 
at the local level for matching purposes?).
    (3) Describes the state laws about obtaining informed consent in 
children and their parents (e.g., assent of children > 7 years of age, 
parental consent) and adolescents for the purposes of conducting an 
intervention. (Parts II and III).
    (4) Describes the state laws for considering an adolescent as an 
``emancipated minor''. (Part III)
    (5) Notes whether the site currently has an IRB which has the 
authority to provide an assurance for the project being proposed or if 
not, whether they will need assistance from CDC in applying for such an 
assurance.
    The degree to which the applicant has met the CDC Policy 
requirements

[[Page 42703]]

regarding the inclusion of women, ethnic, and racial groups in the 
proposed research. This includes:
    1. The proposed plan for the inclusion of both sexes and racial and 
ethnic minority populations for appropriate representation.
    2. The proposed justification when representation is limited or 
absent.
    3. A statement as to whether the design of the study is adequate to 
measure differences when warranted.
    4. A statement as to whether the plans for recruitment and outreach 
for study participants include the process of establishing partnerships 
with community(ies) and recognition of mutual benefits.

3. Provision of HIV/AIDS Report Data to and Collaboration With Local 
Pediatric or Adults HIV/AIDS Surveillance Activities (10 Points)

    a. Adequacy of procedures for collaborating with local health 
department pediatric or adult HIV/AIDS surveillance staff to report 
children or adolescents with HIV exposure, infection, and/or AIDS 
(depending on state law). Includes a signed memorandum of agreement 
detailing the outlined division of responsibilities, joint activities 
to evaluate completeness, timeliness, validity of the HIV/AIDS report 
data, methods to ensure security and confidentiality of HIV/AIDS report 
data, and use of data (Part I.)
    b. Feasibility of plans for completion and computer entry of HIV/
AIDS report forms and complete and timely transfer of HIV/AIDS case 
reports to the local HIV/AIDS surveillance unit.(For Part I)
    c. Adequacy of measures to assure completeness of HIV/AIDS report 
forms, data quality and timeliness, and protection of confidentiality. 
(For Part I)
    d. Adequacy of measures to assure timely reporting of HIV/AIDS 
cases among children and adolescents participating in the intervention 
studies to the local HIV/AIDS surveillance if mandated by state law, 
and to assure protection of confidentiality . (For Parts II and III)

4. Demonstration of Staff's Capability To Conduct Research (20 Points)

    a. Capacity to conduct the proposed activities as evidenced by 
previous experience and scientific expertise. Demonstration that staff 
has:
    (1) Experience working with the targeted population of study 
participants;
    (2) Principal investigators or staff have previous experience and 
scientific expertise in the area of research to be conducted (either in 
epidemiologic research in Part I or behavioral assessment, 
intervention, and evaluation research, including evaluation of cost-
effectiveness, for Parts II and III. ). Include table of current and 
previous relevant research projects, their status, sources and levels 
of funding and principal investigators and list of references of any 
publications on related research by study staff.
    (3) The experience needed to conduct the intervention (e.g., nurse 
counselor, or study coordinator, etc.)
    b. Inclusion of the curriculum vitae for key staff members as well 
as memoranda of agreement that clearly and specifically document 
activities to be performed by any external experts, consultants, or 
collaborating agencies under the cooperative agreement.

5. Staffing, Facilities, and Time Line (20 Points)

    a. Availability of qualified personnel with realistic and 
sufficient percentage-time commitments;
    b. Clarity of the described duties and responsibilities of existing 
and proposed project personnel with epidemiologic, administrative, 
clinical, data management (including HIV/AIDS case reporting to local 
surveillance unit), and statistical responsibilities. Organizational 
chart depicts lines of authority.
    c. Adequacy of clinical oversight of the project, especially 
supervision of data abstraction and entry.
    d. Adequacy of base staff to keep pace with anticipated workload 
such as the biannual medical record review for the number of children 
to be monitored prospectively (Part I) and the interventions involved 
with children (Part II) and adolescents (Part III).
    e. Adequacy of equipment, facilities and systems to be used for 
data abstraction and follow-up tracking, data entry and analysis, 
project management, data security and participant confidentiality.
    f. Feasibility of plans to communicate, ensure quality control and 
consistency, identify and resolve problems, and analyze date in 
collaboration with other sites.
    g. Inclusion of time line showing plan for completion of research 
activities and goals

6. Other (Not Scored)

    a. Budget: The extent to which it is reasonable, clearly justified, 
consistent with the intended use of funds, and allowable. All budget 
categories should be itemized.
    b. Human Subjects: Does the application adequately address the 
requirements of Title 45 CFR part 46 for the protection of human 
subjects? ----Yes No Comments:

H. Other Requirements

Technical Reporting Requirements Provide CDC With Original Plus Two 
Copies of--

    1. annual progress reports;
    2. financial status report, no more than 90 days after the end of 
the budget period; and
    3. final financial status and performance reports, no more than 90 
days after the end of the project period. Send all reports to the 
Grants Management Specialist identified in paragraph J. Where to Obtain 
Additional Information.
    The following additional requirements are applicable to this 
program. For a complete description of each, see Attachment 1 in the 
application kit.

AR-1--Human Subjects Requirements
AR-2--Requirements for Inclusion of Women and Racial and Ethnic 
Minorities in Research
AR-4--HIV/AIDS Confidentiality Provisions
AR-5--HIV Program Review Panel Requirements
AR-6--Patient Care
AR-7--Executive Order 12372 Review
AR-8--Public Health System Reporting Requirements
AR-9--Paperwork Reduction Act Requirements
AR-10--Smoke-Free Workplace Requirements
AR-11--Healthy People 2010
AR-12--Lobbying Restrictions

I. Authority and Catalog of Federal Domestic Assistance Number

    This program is authorized under sections 301(a) and 317(k)(2)of 
the Public Health Service Act (42 U.S.C. 241(a) and 247b(k)(2)), as 
amended. The Catalog of Federal Domestic Assistance number is 93.943.

J. Where To Obtain Additional Information

    This and other CDC announcements can be found on the CDC home page 
Internet address--http://www.cdc.gov Click on ``Funding'' then ``Grants 
and Cooperative Agreements.''
    To receive additional written information and to request an 
application kit, call 1-888-GRANTS4 (1-888-472-6874). You will be asked 
to leave your name and address and will be instructed to identify the 
Announcement number of interest.
    If you have questions after reviewing the contents of all the 
documents, business management technical assistance may be obtained 
from:


[[Page 42704]]


Brenda Hayes, Grants Management Specialist, Grants Management Branch, 
Procurement and Grants Office, Centers for Disease Control and 
Prevention (CDC), Room 3000, 2920 Brandywine Road, Atlanta, GA 30341-
4146, telephone number (770) 488-2741, Email address: [email protected]
For program technical assistance, contact: Jeff Efird, MPA, Deputy 
Chief, Epidemiology Branch, Division of HIV/AIDS Prevention 
Surveillance & Epidemiology, National Center for HIV, STD, TB 
Prevention, Centers for Disease Control and Prevention (CDC), 1600 
Clifton Road, NE., Mailstop E-45, Atlanta, Georgia 30333, Telephone 
(404) 639-6130, [email protected]

    Dated: July 5, 2000.
Ron Van Duyne,
Acting Director, Procurement and Grants Office, Centers for Disease 
Control and Prevention (CDC).
[FR Doc. 00-17445 Filed 7-10-00; 8:45 am]
BILLING CODE 4163-18-P